Is DCTH a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Delcath Systems (DCTH) rests on More treatment centers and more patients per center: HEPZATO sales are a function of active sites and procedure volume. The bear case rests on delcath sells essentially one product for one rare cancer. Analysts covering it publish targets from $25.00 to $36.00 against a $18.79 share price on November 20, 2026, so even the professionals disagree by 38% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
DCTH key stats
At $18.79 on November 20, 2026, Delcath Systems (DCTH) has a market cap of $654M and a P/E of 117.5 on trailing earnings (69.0 on forward earnings).
- Market cap
- $654M
- P/E (trailing)
- 117.5
- P/E (forward)
- 69.0
- EPS (trailing 12 months)
- $0.16
- Price to book
- 4.9
- Beta
- 0.60
Market cap, P/E and yield are measured at the $18.79 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Delcath Systems (DCTH)?
The last two weeks for Delcath Systems, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- DCTH closed at $18.79 on November 20, 2026, down 8.6% over the past five trading days (from $20.55).
- On November 12, 2026, BTIG kept its Buy rating and $25.00 target.
- On November 10, 2026, HC Wainwright & Co. raised its target to $36.00 from $32.00 (Buy).
- On November 9, 2026, BTIG raised its target to $25.00 from $21.00 (Buy).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Delcath Systems, based in New York, develops and sells percutaneous hepatic perfusion (PHP), a procedure that isolates the liver's blood supply, delivers a high dose of the chemotherapy drug melphalan directly to it, and runs the returning blood through filters before it re-enters the body. In the US the product is sold as HEPZATO KIT, approved by the FDA in August 2023 for adults with uveal melanoma (a rare eye cancer) that has spread to the liver and cannot be removed surgically. In Europe the same filtration device is sold as CHEMOSAT. Each HEPZATO treatment is a hospital procedure performed by an interventional radiology and surgical oncology team, so growth depends on how many cancer centers are trained and actively treating patients. The latest quarter was the strongest in the company's history. Revenue for the September 2026 quarter was about $35.1 million, up from about $20.6 million a year earlier, with HEPZATO KIT contributing about $32.7 million and CHEMOSAT about $2.4 million. Gross margin was about 89%, net income was about $7.0 million ($0.17 per diluted share), and adjusted EBITDA was about $11.5 million. HEPZATO volume rose about 72% year over year and the company reported 33 active treatment centers, up from 28 at the end of 2025. Management raised 2026 revenue guidance to $115 million to $117 million, after starting the year at a floor of $100 million and lifting it to $104 million to $108 million in August. The investment picture is a commercial-stage story with a clinical-stage option attached. Delcath has no debt, about $104 million in cash and short-term investments, positive operating cash flow, and a $25 million share buyback (about $16 million left at September 30). The stock has been volatile: it fell sharply in late 2025 when the company cut guidance after a slower quarter, traded near $8 at its lows, and recovered to about $14 by early November 2026 before jumping to about $18.50 after the November 9 third-quarter report. It closed at about $18.78 on November 20, 2026, up about 89% year to date and about 129% over one year, and about 30% over the past month. The open questions are how large the US uveal melanoma market can get, how concentrated sales are among a few hospitals, and whether trials in colorectal and breast cancer liver metastases widen the addressable market several times over.
The bull case: what would have to be true for $36.00
The most optimistic published target on DCTH is $36.00, +91.6% from the $18.79 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. More treatment centers and more patients per center
HEPZATO sales are a function of active sites and procedure volume. Delcath ended 2025 with 28 active centers and reported 33 at the end of September 2026, while procedure volume rose about 72% year over year in the third quarter. Full-year 2026 guidance now assumes HEPZATO volume growth of at least 41% over 2025, up from the 20% assumption in the February outlook. Each new center needs a trained team, hospital formulary approval and a referral flow from ocular oncologists, so onboarding takes months. Growth past the current base depends on new centers ramping and on patients receiving more of the up to six treatments the label allows. Slower volume was the weak spot in late 2025.
2. Profitability and cash generation
Delcath turned profitable in 2025 for the first time in its long history, posting full-year net income of about $2.7 million and adjusted EBITDA of about $25.1 million on $85.2 million of revenue. In 2026 the margin picture improved: nine-month net income was about $8.6 million, third-quarter gross margin was about 89%, and quarterly operating cash flow was about $8.2 million. Operating expenses are rising, with third-quarter R&D at about $11.0 million and SG&A at about $13.1 million, because the company is funding three randomized trials from its own cash. The $25 million buyback authorized in November 2025 had retired about 946,000 shares at an average near $9.51 by September 30, 2026.
3. Colorectal and breast cancer trials
The larger long-term question is whether liver-directed melphalan works in more common cancers. A Phase 2 trial in metastatic colorectal cancer with liver involvement, about 90 patients in the third-line setting, compares HEPZATO plus trifluridine-tipiracil and bevacizumab against those two drugs alone. Enrollment began in the third quarter of 2025 and the primary hepatic progression-free survival readout is expected by the end of 2027, with overall survival in 2028. The DELUMA trial in HER2-negative breast cancer with liver-dominant disease dosed its first patient in July 2026 and targets about 90 patients, with a primary readout expected by the end of 2028. Both populations are far larger than uveal melanoma.
4. Pipeline extensions and Europe
Beyond the two Phase 2 trials, Delcath plans an IND submission in cholangiocarcinoma (bile duct cancer) in early 2027 and expects to finish preclinical work on an oxaliplatin-based PHP product by mid-2027, pending FDA agreement. Oxaliplatin is a standard colorectal cancer drug, so a second chemotherapy option could matter more than the melphalan kit in that indication. In Europe, CHEMOSAT revenue was about $2.4 million in the third quarter, up from about $1.3 million a year earlier, helped by a two-year reimbursement approval in Sweden's Vastra Gotaland region in 2025. The CHOPIN trial run by Leiden University Medical Center reported one-year progression-free survival of about 54.7% with PHP plus ipilimumab and nivolumab, versus about 15.8% with PHP alone.
The bear case: what would have to be true for $25.00
The most pessimistic published target is $25.00, +33.0% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Delcath Systems is worth if the risks below bite instead of the drivers above.
Delcath sells essentially one product for one rare cancer. Uveal melanoma affects only a few thousand people a year in the US, and only a portion of them develop liver metastases that fit the HEPZATO label, so the current market has a ceiling. Sales are concentrated: two customers accounted for about 31% of revenue in the first nine months of 2026, and a third for about 6.5%, so a slowdown at one large hospital shows up quickly in the numbers. The fourth quarter of 2025 showed how lumpy volume can be, with a net loss of about $1.9 million after a guidance cut that sent the stock sharply lower. The procedure carries serious side effects, including blood count suppression, and the FDA label includes a boxed warning and a restricted distribution program, which limits how fast new sites can start. Competing systemic drugs, such as Immunocore's Kimmtrak and newer targeted agents in development, could change treatment sequencing. The colorectal and breast trials are randomized Phase 2 studies and may not succeed. Pricing and reimbursement, including 340B discounts and the Medicaid rebate agreement, can pressure realized prices. At about 5.9 times trailing sales and roughly 69 times forward earnings estimates, after a gain of about 89% in 2026, the valuation already assumes continued growth.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding DCTH already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on DCTH
5 analysts cover DCTH, with an average target of $28.60 (+52.2% against $18.79) and a split of 5 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the DCTH forecast and price target page.
How is DCTH valued?
Market cap, P/E and dividend yield at today's price are in the DCTH key stats above. The business figures below come from Delcath Systems's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$110 million
- Revenue growth (Q3 2026, year over year): ~70%
- Net income (TTM): ~$6.7 million
- Gross margin (Q3 2026): ~89%
- Cash and investments (no debt): ~$104 million
As of November 2026: At about $18.78 a share (November 20, 2026) and roughly 36 million shares including pre-funded warrants, Delcath is valued near $650 million, or about 5.9 times trailing revenue and roughly 5.0 times after netting out cash. Trailing earnings are small, about $6.7 million once the fourth-quarter 2025 loss is included, so the price-to-earnings ratio is very high and swings with each quarter. Guidance of $115 million to $117 million for 2026 implies fourth-quarter revenue of roughly $26 million to $28 million, below the third quarter's $35.1 million, which suggests management is leaving room for uneven volume. Published analyst targets earlier in 2026 ranged from roughly $19 to $30, and the average of five targets tracked by Yahoo Finance is about $28.60.
How do you decide if DCTH is a buy?
Whether DCTH is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold DCTH indirectly through an index or sector ETF before adding more.
What would change your mind on DCTH
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: More treatment centers and more patients per center stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: delcath sells essentially one product for one rare cancer fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the DCTH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about DCTH against your real portfolio and see your actual exposure before deciding.
Your questions about Delcath Systems
Ask Walnut's AI anything about DCTH and see how it fits what you own.
FAQ
Is DCTH a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on More treatment centers and more patients per center, with revenue (ttm) at ~$110 million. The bear case rests on delcath sells essentially one product for one rare cancer. Analysts covering it are spread from $25.00 to $36.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell DCTH?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Delcath sells essentially one product for one rare cancer. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $25.00, +33.0% from the $18.79 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for DCTH?
+
More treatment centers and more patients per center. HEPZATO sales are a function of active sites and procedure volume. The most optimistic analyst target on DCTH is $36.00, +91.6% from the $18.79 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for DCTH?
+
Delcath sells essentially one product for one rare cancer. Uveal melanoma affects only a few thousand people a year in the US, and only a portion of them develop liver metastases that fit the HEPZATO label, so the current market has a ceiling. Sales are concentrated: two customers accounted for about 31% of revenue in the first nine months of 2026, and a third for about 6.5%, so a slowdown at one large hospital shows up quickly in the numbers. The fourth quarter of 2025 showed how lumpy volume can be, with a net loss of about $1.9 million after a guidance cut that sent the stock sharply lower. The procedure carries serious side effects, including blood count suppression, and the FDA label includes a boxed warning and a restricted distribution program, which limits how fast new sites can start. Competing systemic drugs, such as Immunocore's Kimmtrak and newer targeted agents in development, could change treatment sequencing. The colorectal and breast trials are randomized Phase 2 studies and may not succeed. Pricing and reimbursement, including 340B discounts and the Medicaid rebate agreement, can pressure realized prices. At about 5.9 times trailing sales and roughly 69 times forward earnings estimates, after a gain of about 89% in 2026, the valuation already assumes continued growth. The most pessimistic published target is $25.00, +33.0% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Delcath Systems do?
+
Delcath Systems sells HEPZATO KIT, an FDA-approved liver-directed chemotherapy system for metastatic uveal melanoma, and CHEMOSAT in Europe.
What would have to change for DCTH to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (More treatment centers and more patients per center) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (delcath sells essentially one product for one rare cancer) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Delcath Systems do?
+
Delcath develops and sells percutaneous hepatic perfusion, a procedure that isolates the liver's blood circulation so doctors can deliver a high dose of melphalan chemotherapy directly to liver tumors. Catheters placed through blood vessels carry the drug in, and blood leaving the liver passes through Delcath's filters to remove most of the drug before returning to the rest of the body. In the US the product is called HEPZATO KIT and is approved for uveal melanoma that has spread to the liver and cannot be surgically removed. In Europe the filtration device is sold as CHEMOSAT. The company also runs Phase 2 trials testing the approach in colorectal and breast cancer liver metastases, and plans a bile duct cancer study.
How did Delcath do in the third quarter of 2026?
+
Delcath reported third-quarter 2026 results on November 9, 2026. Revenue was about $35.1 million, up from about $20.6 million a year earlier, made up of about $32.7 million from HEPZATO KIT in the US and about $2.4 million from CHEMOSAT in Europe. Gross margin was about 89%, net income was about $7.0 million or $0.17 per diluted share, and adjusted EBITDA was about $11.5 million. HEPZATO procedure volume grew about 72% from the prior-year quarter, the company had 33 active treatment centers, and operating cash flow was about $8.2 million. Management raised full-year 2026 revenue guidance to $115 million to $117 million and kept a gross margin range of 87% to 89%.
Is Delcath profitable?
+
Yes, on a GAAP basis, though the profits are recent and small. After decades of losses, Delcath reported full-year 2025 net income of about $2.7 million on $85.2 million of revenue, compared with a net loss of about $26.4 million in 2024. The fourth quarter of 2025 was a loss of about $1.9 million, which shows profitability can slip in a slower quarter. In 2026 results improved: nine-month net income was about $8.6 million, or $0.21 per diluted share. Over the trailing twelve months net income is roughly $6.7 million. The company also reports positive adjusted EBITDA and positive operating cash flow, and has no debt.
Walnut is informational, not investment advice, and gives no verdict on DCTH. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.